DNA º¹±¸¾à ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
DNA Repair Drugs Market, By Drug Type, By Application, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå
:
1672854
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è DNA º¹±¸¾à ½ÃÀåÀº 2025³â 80¾ï 5,000¸¸ ´Þ·¯, 2032³â¿¡´Â 192¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 13.3%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ »ó¼¼ ³»¿ë |
±âÁØ ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
80¾ï 5,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR |
13.30% |
2032³â ±Ý¾× ¿¹Ãø |
192¾ï 9,000¸¸ ´Þ·¯ |
±×¸². 2025³â Áö¿ªº° DNA º¹±¸¾à ½ÃÀå Á¡À¯À²(%)

DNA º¹±¸¾àÀº ¼¼Æ÷°¡ ¼Õ»óµÈ DNA¸¦ ½Äº°ÇÏ°í º¹±¸ÇÏ´Â ´É·ÂÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϸç, ¾Ï ¹× À¯Àüü ºÒ¾ÈÁ¤¼º°ú °ü·ÃµÈ ±âŸ Áúº´ Ä¡·á¿¡ Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÀÎü ³» DNA´Â ȯ°æ ³ëÃâ ¹× ±âŸ ¼¼Æ÷ °úÁ¤À¸·Î ÀÎÇØ ÀÚ¿¬ÀûÀ¸·Î ¼ÒÁøµÇ¾î ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Àý´Ü ¹× ±âŸ À¯ÇüÀÇ ¼Õ»óÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¤»óÀûÀÎ »óȲ¿¡¼ ¼¼Æ÷´Â ÀÌ·¯ÇÑ ¼Õ»óÀ» º¹±¸ÇÏ°í µ¹¿¬º¯ÀÌÀÇ ÃàÀûÀ» ¹æÁöÇϱâ À§ÇØ ÁøÈÀûÀ¸·Î ÃÖÀûÈµÈ DNA º¹±¸ °æ·Î¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀϺΠº´Àû »óÅ´ DNA º¹±¸ ´É·ÂÀÇ °á¼Õ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¾àÇÐÀûÀ¸·Î DNA º¹±¸ ¸ÞÄ¿´ÏÁòÀ» °ÈÇÏ´Â °ÍÀº ¹ÌÃæÁ· ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¸î¸î »ý¸í°øÇÐ ±â¾÷ ¹× ´ëÇü Á¦¾à»çµéÀº PARP, ATR, ATM ¹× ±âŸ DNA ¼Õ»ó ¹ÝÀÀ¿¡ °ü¿©ÇÏ´Â ºÐÀÚ¿Í °°Àº DNA º¹±¸ °æ·ÎÀÇ ÁÖ¿ä ´Ü¹éÁúÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â DNA º¹±¸¾àÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß´Â ¾Ï ¹× À¯Àü¼º ÁúȯÀÇ Á¤¹ÐÄ¡·áÁ¦ °³¹ß¿¡ À¯¸ÁÇÑ ºÐ¾ßÀÔ´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°è DNA º¹±¸¾à ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í DNA ¼Õ»ó°ú ´Ù¾çÇÑ Áúº´ ¹ßº´ÀÇ ¿¬°ü¼º¿¡ ´ëÇÑ ÀÓ»óÀû Á߿伺ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, DNA º¹±¸ °æ·ÎÀÇ ºÐÀÚ Ç¥Àû ¹ß±¼À» À§ÇÑ ÀǾàǰ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡¿Í ´Ù¾çÇÑ Èĺ¸¹°Áú¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè ÁøÇàÀº ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª DNA »ý¹°Çаú °ü·ÃµÈ º¹À⼺°ú ¿ÀÇÁ Ÿ°Ù È¿°ú¿Í °ü·ÃµÈ ¾ÈÀü¼º À§ÇèÀº ¿ÏÀüÇÑ ÀÌÇØ¿Í ÀÓ»ó Àû¿ëÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ôÀº °³¹ß ºñ¿ëµµ ½ÃÀå °³Ã´¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¾÷°è´Â ¹ÝÀÀÀÚ È¯ÀÚ±ºÀ» ¼±º°Çϱâ À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ Àü·«°ú µ¶¼ºÀ» ÃÖ¼ÒÈÇÏ¸é¼ È¿´ÉÀ» ±Ø´ëÈÇϱâ À§ÇÑ º´¿ë¿ä¹ý Á¢±Ù¹ý¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÇâÈÄ ½Å¾à °³¹ß ³ë·ÂÀº ¾Ï ÀÌ¿ÜÀÇ ´Ù¸¥ ºÐ¾ß·Î È®ÀåµÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è DNA º¹±¸¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- DNA º¹±¸¾à ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è DNA º¹±¸¾à ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map (COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- ½ÃÀå µ¿Çâ
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
- ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
- PEST ºÐ¼®
- PorterÀÇ Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ÀüüÀûÀÎ ¿µÇâ
- Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
- ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
Á¦6Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå, ¿ëµµº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ³¼Ò¾Ï
- À¯¹æ¾Ï
- Àü¸³¼±¾Ï
- Æó¾Ï
- º¹¸·¾Ï
- ±âŸ
Á¦7Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â(10¾ï ´Þ·¯)
Á¦8Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- º´¿ø ¾à±¹
- ¼Ò¸Å ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦9Àå ¼¼°èÀÇ DNA º¹±¸¾à ½ÃÀå, Áö¿ªº°, 2020-2032³â(10¾ï ´Þ·¯)
- ¼·Ð
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- ¾ÆÇÁ¸®Ä«
Á¦10Àå °æÀï ±¸µµ
- ±â¾÷ °³¿ä
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Clovis Oncology
- Johnson & Johnson Services, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc(GSK)
- Novartis AG
- Roche Holding AG
- Agios Pharmaceuticals, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- BioMarin Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited
- NMS Group
Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×
- À¶¼º°ú ¼èÅð
- Coherent Opportunity Map
Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
LSH
¿µ¹® ¸ñÂ÷
Global Dna Repair Drugs Market is estimated to be valued at USD 8.05 Bn in 2025 and is expected to reach USD 19.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 13.3% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 8.05 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
13.30% |
2032 Value Projection: |
USD 19.29 Bn |
Figure. Dna Repair Drugs Market Share (%), By Region 2025

DNA repair drugs aim to improve the ability of cells to identify and repair damaged DNA, which could have applications in treating cancer and other diseases related to genomic instability. DNA in the human body undergoes natural wear and tear from environmental exposures and other cellular processes that can cause breaks and other types of damage over time. Under normal circumstances, cells have evolutionarily optimized DNA repair pathways to fix such lesions and prevent mutations from accumulating. However, certain medical conditions are linked to deficiencies in DNA repair capacity. Enhancing DNA repair mechanisms pharmaceutically could help address unmet clinical needs. Several biotechs and big pharmaceutical firms are researching DNA repair drugs that target key proteins in repair pathways such as PARP, ATR, ATM and other molecules involved in DNA damage response. This budding field holds promise for developing precision medicines for cancer and genetic disorders.
Market Dynamics:
Global DNA repair drugs market growth is driven by rising cancer burden worldwide and growing clinical emphasis on DNA damage links to various disease pathogenesis. Furthermore, increasing pharmaceutical R&D investments to identify molecular targets in DNA repair pathways and ongoing clinical trials for various candidates can offer lucrative opportunities for market players. However, complexities associated with DNA biology and safety risks pertaining to off-target effects can hamper complete understanding and clinical translation. High costs of development can hamper the market growth. Industry players are focused on biomarker strategies to select responder patient populations and combination therapy approaches to maximize efficacy while minimizing toxicity. Future discovery efforts can expand the scope into non-oncology areas.
Key Features of the Study:
- This report provides in-depth analysis of the global DNA repair drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global DNA repair drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Genentech, Pfizer, AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market
Detailed Segmentation-
- By Drug Type
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Route of Administration
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer Inc.
- Clovis Oncology
- Johnson & Johnson Services, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc (GSK)
- Novartis AG
- Roche Holding AG
- Agios Pharmaceuticals, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- BioMarin Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited
- NMS Group
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Application
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global DNA Repair Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global DNA Repair Drugs Market, By Drug Type, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Niraparib (Zejula)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Olaparib (Lynparza)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rucaparib (Rubraca)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Talazoparib (Talzenna)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global DNA Repair Drugs Market, By Application, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Ovarian Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Peritoneal Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global DNA Repair Drugs Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global DNA Repair Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global DNA Repair Drugs Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- AstraZeneca PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Clovis Oncology
- Johnson & Johnson Services, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline plc (GSK)
- Novartis AG
- Roche Holding AG
- Agios Pharmaceuticals, Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- BioMarin Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited
- NMS Group
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
°ü·ÃÀÚ·á